daclizumab (Zinbryta)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

What is daclizumab, and how does it work?

  • Daclizumab (Zinbryta) is an injectable medication used for treating multiple sclerosis (MS). Its mechanism of action is not completely understood. Available data suggests that it may work by modifying immune processes that may be responsible for causing MS by interfering with the activation of lymphocytes (a type of white blood cell) that cause inflammation and destruction of nerves in patients with MS. Daclizumab does not cure MS. It decreases the number of MS flares and lesions.
  • The FDA approved daclizumab in May, 2016.

What brand names are available for daclizumab?

  • Zinbryta is the brand name for daclizumab available in the US.

Is daclizumab available as a generic drug?

  • No, this drug is not available as a generic.

Do I need a prescription for daclizumab?

  • Yes, you need a prescription for this drug.

What are the uses for daclizumab?

  • Daclizumab is used for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).
  • It is reserved for patients who have had an inadequate response to two or more MS drugs because of its safety profile.

Why is there a black box warning for daclizumab?

  • Daclizumab can cause severe liver injury including life-threatening events, liver failure, and autoimmune hepatitis. Transaminase and bilirubin levels should be obtained before starting daclizumab, monthly during treatment, and up to 6 months after the last dose.
  • It should not be used in patients with liver problems.
  • This drug can cause immune-mediated disorders including skin reactions, lymphadenopathy (enlargement of lymph nodes), non-infectious colitis, and other immune-mediated disorders. These conditions may require treatment with oral or injectable corticosteroids or medication to suppress the immune system.
  • Daclizumab is available only through a restricted distribution program called the ZINBRYTA REMS Program.

What are the side effects of daclizumab?

Common side effects include:

Other side effects include:

Other less common side effects include:

Possible serious side effects include:

  • Liver damage
  • Immune mediated disorders (for example, skin reactions, colitis)
  • Serious allergic reactions (anaphylaxis, angioedema)
  • Severe infections
  • Depression
  • Suicidal thoughts, Suicide
  • Decreased numbers of white blood cells
  • Severe skin reactions
  • Non-infectious colitis
Medically Reviewed by a Doctor on 1/27/2017

Quick GuideMultiple Sclerosis (MS) Symptoms and Treatment

Multiple Sclerosis (MS) Symptoms and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors